Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer

被引：0
|
作者：
Thehang Luu
Kyu-pyo Kim
Suzette Blanchard
Bean Anyang
Arti Hurria
Lixin Yang
Jan H. Beumer
George Somlo
Yun Yen
机构：
[1] City of Hope Medical Center,Department of Medical Oncology
[2] OncoGambit,Cancer Therapeutics Program
[3] LLC,Department of Oncology, Asan Medical Center
[4] University of Pittsburgh Cancer Institute,Department of Biostatistics
[5] University of Ulsan College of Medicine,Department of Molecular
[6] City of Hope,Department of Pharmaceutical Sciences
[7] City of Hope,Division of Hematology/Oncology, Department of Medicine
[8] University of Pittsburgh School of Pharmacy,Pharmacology, Beckman Research Institute
[9] University of Pittsburgh School of Medicine,Cancer Research and Drug Discovery Medical Technology College
[10] City of Hope,undefined
[11] Taipei Medical University,undefined
来源：
Breast Cancer Research and Treatment | 2018年 / 167卷
关键词：
Phase IB clinical trial; Ixabepilone; Vorinostat; Metastatic breast cancer; Histone deacetylation inhibitors (HDACIs);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：469 / 478
页数：9
相关论文
共 50 条
  • [31] A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Sperinde, J.
    Huang, W.
    Chen, W. Y.
    Savoie, J.
    Fornier, M.
    Winer, E. P.
    Bunnell, C.
    Krop, I. E.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1841 - 1847
  • [32] Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer
    Ibrahim, Nuhad K.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [33] Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
    Edgardo Rivera
    Henry Gomez
    Breast Cancer Research, 12
  • [34] Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
    Cristofanilli, Massimo
    JOURNAL OF ONCOLOGY, 2012, 2012
  • [35] Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
    Puhalla, Shannon
    Brufsky, Adam
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (03): : 505 - 515
  • [36] Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer
    Li, Lun
    Li, Jiang
    Yang, Kehu
    Tian, Jinhui
    Sun, Tiantian
    Jia, Wenqin
    Zhang, Peng
    Yi, Kang
    FUTURE ONCOLOGY, 2010, 6 (02) : 201 - 207
  • [37] Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
    Rivera, Edgardo
    Gomez, Henry
    BREAST CANCER RESEARCH, 2010, 12
  • [38] Severe Cardiotoxicity Associated with Ixabepilone Use in Metastatic Breast Cancer
    Santiago, Michael J.
    Hayes, Bryan D.
    Butler, Kenneth H.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (04) : E17 - +
  • [39] Nail disorders in a woman treated with ixabepilone for metastatic breast cancer
    Alimonti, A
    Nardoni, C
    Papaldo, P
    Ferretti, G
    Caleno, MP
    Carlini, P
    Fabi, A
    Rasio, D
    Vecchione, A
    Cognetti, F
    ANTICANCER RESEARCH, 2005, 25 (05) : 3531 - 3532
  • [40] Phase I/IB trial of eribulin and everolimus in patients with triple-negative metastatic breast cancer.
    Luu, Thehang H.
    Blanchard, Suzette
    Yim, John Hosei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345